Risultati per: Trattamento dell'infezione da Helicobacter Pylori

Helicobacter pylori
Infection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle leads to the recommendation that all infected patients should receive treatment. In the context of the wide clinical spectrum associated with Helicobacter pylori gastritis, specific issues persist and require regular updates for optimised management.
The identification of distinct clinical scenarios, proper testing and adoption of effective strategies for prevention of gastric cancer and other complications are addressed. H. pylori treatment is challenged by the continuously rising antibiotic resistance and demands for susceptibility testing with consideration of novel molecular technologies and careful selection of first line and rescue therapies. The role of H. pylori and antibiotic therapies and their impact on the gut microbiota are also considered.
Progress made in the management of H. pylori infection is covered in the present sixth edition of the Maastricht/Florence 2021 Consensus Report, key aspects related to the clinical role of H. pylori infection were re-evaluated and updated. Forty-one experts from 29 countries representing a global community, examined the new data related to H. pylori infection in five working groups: (1) indications/associations, (2) diagnosis, (3) treatment, (4) prevention/gastric cancer and (5) H. pylori and the gut microbiota. The results of the individual working groups were presented for a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in various clinical fields.

In the pathogenesis of gastric cancer, Helicobacter pylori infection was the most important risk factor for noncardia gastric cancer. Recently, the US Department of Health and Human Services had again identified H pylori as a human carcinogen in its 15th Report on Carcinogens,1 which has sparked global concern. However, the exact mechanism by which H pylori induces gastric carcinogenesis remains unclear. In their article in Gastroenterology, Zhang et al2 found a link between H pylori infection, inflammation, and fibroblast growth factor (FGF) receptor 4 (FGFR4) activation, where SRC mediated a feed-forward activation loop between FGFR4 and signal transducer and activator of transcription 3 (STAT3) in response to H pylori infection.